CPD-Accredited | Cutting Edge Therapeutic Approaches for Duchenne Muscular Dystrophy

6 February 2024

Together with Muscular Dystrophy Canada (MDC) we are pleased to invite you to a webinar on therapies for Duchenne muscular dystrophy. This webinar is primarily targeted at Canadian clinicians, academics, and trainees with an interest in neuromuscular disease. This is an independent clinical/academic webinar with no industry sponsorship or influence, and NMD4C and MDC are providing organizational and technical support.

Learning Objectives

  1. Understanding the muscle stem cell deficit in DMD.
  2. Development of small drugs that enhance muscle regeneration by mobilizing muscle stem cells.
  3. To review the benefits and challenges of classic glucocorticoid therapy (prednisone, deflazacort) for the treatment of DMD
  4. To discuss VBP15 (vamorolone), a novel “dissociative steroid” developed with the goal to separate the anti-inflammatory benefits of steroid therapy from the well-known adverse effects
  5. To summarize the results of clinical trials in ambulatory boys with DMD that highlight the impact of vamorolone on muscle, bone and endocrine outcomes

The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Date: Feb 06 2024

Time: 17:00 ET

Further details

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern